St. Jude Medical (STJ) Announces First Patient Enrollment in EnligHTN III Renal Denervation Study of Next-Generation EnligHTN System
5/14/2013 10:11:12 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced enrollment of the first patient in the EnligHTN III trial. This study will evaluate the safety and performance of the new second-generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.The next-generation system utilizes the proven multi-electrode catheter paired with a new generator that features a high-tech, icon-friendly, touch screen user interface that provides simultaneous ablations using four electrodes. This advancement reduces total ablation time from approximately 24 minutes to four minutes. With its unique non-occlusive basket design, each placement of the ablation catheter using the EnligHTN system administers a predictable treatment pattern while allowing for continuous blood flow to the kidney throughout the procedure. Additionally, the new second-generation EnligHTN generator allows physicians to easily view and record procedure information.
Help employers find you! Check out all the jobs and post your resume.
comments powered by